Annual Drug Patent Expirations for RELISTOR
Relistor is a drug marketed by Salix Pharms and Salix and is included in two NDAs. It is available from one supplier. There are fourteen patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for RELISTOR.
This drug has one hundred and twenty patent family members in thirty-eight countries.
The generic ingredient in RELISTOR is methylnaltrexone bromide. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
